Cangene (FRA:YGE) EPS (Basic) : €-0.09 (TTM As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene EPS (Basic)?

Cangene's basic earnings per share (Basic EPS) for the three months ended in Oct. 2013 was €-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Oct. 2013 was €-0.09.

Cangene's EPS (Diluted) for the three months ended in Oct. 2013 was €-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2013 was €-0.09.

Cangene's EPS without NRI for the three months ended in Oct. 2013 was €-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Oct. 2013 was -0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cangene EPS (Basic) Historical Data

The historical data trend for Cangene's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene EPS (Basic) Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

EPS (Basic)

Get a 7-Day Free Trial

0.57

0.09

0.01

-0.34

0.02

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
EPS (Basic)	Get a 7-Day Free Trial															0.05	-0.04	0.05	-0.04	-0.06

Cangene EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cangene's Basic EPS for the fiscal year that ended in Jul. 2013 is calculated as

Basic EPS (A: Jul. 2013 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(1.038	-	0)	/	66.747
	=	0.02

Cangene's Basic EPS for the quarter that ended in Oct. 2013 is calculated as

Basic EPS (Q: Oct. 2013 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.822	-	0)	/	66.747
	=	-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.09

Cangene (FRA:YGE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cangene EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cangene's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines